Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil pills could help fight prostate cancer, new study hints

NCT ID NCT02333435

Disease control Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether taking omega-3 (EPA) supplements can reduce inflammation and slow cancer cell growth in men with high-risk prostate cancer who choose surgery. 130 participants will take either EPA capsules or a placebo for 14 months, starting before surgery. Researchers will measure changes in tumor growth markers and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Omega-3 (EPA) dietary supplement
What this could lead to
If it works, this could point toward a simple dietary supplement to help control prostate cancer growth and improve quality of life after surgery.
What could go wrong
This is an early phase 2 trial with only 130 participants. The supplement may not show a clear benefit, and results may not apply to all prostate cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

130 people

The number who actually took part.

Started

Feb 2015

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prostate cancer (Gleason score \>= 7) * Patient has chosen to undergo radical prostatectomy * Patient agrees to stop taking any omega-3 supplements at least 3 months before the start of the study * Patient has provided informed consent Exclusion Criteria: * Allergy to fish and sunflower * Suffering from a bipolar disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High-risk prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperplasia Inflammation prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Centre de Recherche Clinique et Evaluative en Oncologie - Hotel Dieu de Quebec

    Québec, Quebec, G1R 3S1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.